National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Ewing Family of Tumors Treatment (PDQ®)     
Last Modified: 08/07/2009
Health Professional Version
Changes to This Summary (08/07/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview 1

Added Goldsby et al. as reference 47 2 and level of evidence 3iiiDi.

Added text 2 to state that the cumulative risk of developing a secondary solid tumor at 10 years after diagnosis appears to be about 1.8%, although this may be higher with longer follow-up.

Ewing Tumor of Bone: Recurrent Tumors 3

Added Gardner et al. as reference 11 4 and level of evidence 3iiiDiii.

Added Gilman et al. as reference 13 4.

Added Eapen as reference 14 4.

Added text 5 to state that COG-ADVL0821 6 is a phase II trial of cixutumumab, an anti-IGF1 receptor monoclonal antibody.


Table of Links

1http://www.cancer.gov/cancertopics/pdq/treatment/ewings/HealthProfessional/28.c
dr#Section_28
2http://www.cancer.gov/cancertopics/pdq/treatment/ewings/HealthProfessional/142.
cdr#Section_142
3http://www.cancer.gov/cancertopics/pdq/treatment/ewings/HealthProfessional/51.c
dr#Section_51
4http://www.cancer.gov/cancertopics/pdq/treatment/ewings/HealthProfessional/225.
cdr#Section_225
5http://www.cancer.gov/cancertopics/pdq/treatment/ewings/HealthProfessional/218.
cdr#Section_218
6http://www.cancer.gov/search/viewclinicaltrials.aspx?version= heal
thprofessional &cdrid=633186